Építés alatt – nem éles oldal
Belépés
Leállítva1/2. fázis

Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC

A legfontosabb adatok

Ki végzi
Galera Therapeutics, Inc.
Hol
Cleveland, Columbus, Dallas, Durham, Greeley, Iowa City, Loveland, Spartanburg és Spokane (Egyesült Államok)Mind a 10 helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
1/2. fázis
Résztvevők
47 fő vett részt
Kezdés
2020. okt. 18.
Befejezés
2023. nov. 28.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • GC4711 +SBRT
  • Placebo +SBRT
A regiszteradat frissítve
2024. április 30.
Miért állt le
Development GC4711 was halted after the lead study in pancreatic cancer was stopped early due to meeting the requirements of a futility analysis

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 19 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female subjects at least 18 years of age
  • Ability to understand and the willingness to sign a written informed consent
  • Histological or biopsy proven NSCLC
  • ECOG performance status of 0-3
  • Node negative (T1 to T3N0M0), centrally located (within 2cm in all directions around the proximal bronchial tree, including ultra-central tumors, abutting the bronchial tree or trachea) or large (>1-7cm) Non-Small Cell Lung Cancer (NSCLC), judged acceptable for SBRT by the treating Investigator
  • Adequate end-organ function, based on routine clinical and laboratory workup:; ANC >1,000 cells/µl, Platelets ≥ 75,000 cells/µl, Hemoglobin ≥ 7.0 g/dl; Serum creatinine ≤ 2 x ULN or calculated creatinine clearance ≥ 30 ml/min; Total bilirubin ≤ 1.5 x ULN (or direct bilirubin below the ULN), AST and ALT ≤ 2.5 x ULN
  • Males and females of must agree to use effective contraception starting prior to the first day of treatment and continuing after the last dose of GC4711/Placebo for 30 days (females) and 90 days (males)

Ki nem vehet részt

  • Prior treatment with immunotherapy within 3 months prior to Day 1 dosing
  • Prior intra-thoracic radiotherapy or surgery with substantial overlap to planned radiation fields as determined by the treating radiation oncologist
  • Subjects not recovered/controlled from prior treatment-related (chemotherapy or targeted therapy) toxicities judged by treating physician
  • Participation in other clinical trials actively testing new anti-cancer treatments, unless previously written approval is provided by the Sponsor
  • Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure
  • Subjects with confirmed nodal and/or distant disease(including brain), according standard workup by local investigator
  • Uncontrolled malignancy other than lung cancer that requires active treatment or is deemed by the treating physicians to be likely to affect the subject's survival duration
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to GC4711
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements
  • Any other conditions that, in the Investigator's opinion, might indicate the subject to be unsuitable for the study
  • Subjects with peripheral lesions 1cm or smaller
  • Female subjects who are pregnant or breastfeeding

Helyszínek itt: Egyesült Államok

  • University Hospitals Cleveland Medical Center*Cleveland, Egyesült Államok
  • IACT HealthColumbus, Egyesült Államok
  • Parkland Health and Hospital SystemDallas, Egyesült Államok
  • The University of Texas Southwestern Medical CenterDallas, Egyesült Államok
  • Duke University Medical CenterDurham, Egyesült Államok
  • Banner MD Anderson Cancer Center at NCMCGreeley, Egyesült Államok
  • University of Iowa Hospitals and ClinicsIowa City, Egyesült Államok
  • Banner McKee Medical CenterLoveland, Egyesült Államok
  • Gibbs Cancer Center & Research InstituteSpartanburg, Egyesült Államok
  • Cancer Care NorthwestSpokane, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

GTI-4711-101 is a Phase I/II study of the safety of GC4711, its effect on in-field tumor response and its potential to reduce radiation-related pulmonary injury due to SBRT for lymph node negative (T1 to T3N0M0) peripheral or central localized (within 2cm of the proximal bronchial tree) NSCLC.

A teljes eredeti leírásKevesebb

After an open-label, Phase 1, safety cohort of 5 subjects has been completed, a randomized, placebo-controlled Phase 2 portion of 66 subjects will be conducted.

A vizsgálat 3 csoportja

  • Phase 1 GC4711 + SBRTA vizsgált kezelés

    Kezelés: GC4711 +SBRT

  • Phase 2 Placebo + SBRTPlacebo, összehasonlításként

    Kezelés: Placebo +SBRT

  • Phase 2 GC4711 +SBRTA vizsgált kezelés

    Kezelés: GC4711 +SBRT

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation Therapy (SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell Lung Cancer (NSCLC)
A regiszteradat frissítve
2024. április 30.